Naltrexone

New MyPhenomeTM test delivers patients and providers with most comprehensive and actionable insights yet into their obesity type(s). MENLO PARK, Calif., April 4, 2024 /PRNewswire/ -- Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces today the launch of a new MyPhenomeTM test that now allows patients to test for all three identified phenotypes - Emotional Hunger, Hungry Gut and Hungry Brain - in one simple test. For the first time, the new test gives deeper insights into the presence of one or more phenotypes, how that influences an individual's obesity, and an in-depth MyPhenome test report personalized to the patient. Obesity phenotypes are the combination of genes and other biometric data that cause obesity, first discovered by Phenomix's co-founders and Mayo Clinic physicians, Andres Acosta, M.D. Ph.D. and Michael Camilleri, M.D. D.Sc. Phenomix co-founders previously identified that patients can exhibit multiple phenotypes, with a primary (leading) phenotype and one or more underlying phenotypes. A 2024 study links patients with multiple phenotypes to higher body weight and body mass index. Notably, obesity treatments tailored to a patient's phenotype(s) are twice as effective as other one-size-fits-all treatments. The new MyPhenome test and report will outline a patients' identified phenotype(s) and personalized context behind the cause of their obesity. From there, patients can log into the MyPhenome portal for additional resources, including specific meal plans and recipes that complement their phenotype. It also helps providers develop precise and effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations. The three phenotypes now available in the MyPhenome test, include: Emotional Hunger - Individuals who eat in response to emotional triggers and are characterized by high levels of cravings, anxiety, and depression. Treatment can include cognitive therapy and medications such as Naltrexone/bupropion (Contrave), that decrease emotional eating and increase self-awareness. Hungry Gut - Patients with abnormal satiety have accelerated gastric emptying. Treatment can include the "Hungry Gut Diet," medications such as semaglutide (GLP-1s), and certain devices and bariatric surgeries. Hungry Brain - Patients with abnormal satiation require more calories at each meal to reach maximal fullness. Treatment can include the "Hungry Brain Diet," medications such as phentermine-topiramate (Qsymia), and certain devices and bariatric surgeries. "The release of our newest test is a testament of our commitment to further understand the complexity of obesity and find ways to solve it," said Mark Bagnall, CEO of Phenomix Sciences. "This test goes beyond simply providing a yes or no answer; it offers a deeper understanding of the degree to which these phenotypes affect each patient and provides actionable ways to address it. Backed by powerful machine learning and groundbreaking research, this is just the beginning of unlocking the potential of obesity precision medicine." Phenomix continues to deploy AI tools to analyze genetic and other biological data to understand how phenotypes influence an individual's obesity and to facilitate the continued advancement of these patient-centric insights. The new MyPhenome test is now available to providers across the U.S. If you are interested in offering the test to patients or learning more, visit . About Phenomix Sciences Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity globally through the use of our proprietary genetic tests, unique data sets and advanced analytics. Mayo Clinic physicians, scientists, and researchers, Andres Acosta, M.D. Ph.D., and Michael Camilleri, M.D. D.Sc., founded the company after 10 years of rigorous clinical research focused on uncovering the pathophysiology behind the variability in response to obesity treatments. Phenomix believes that the key to understanding obesity is its unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence for yielding better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients. For more information, please visit . Media Contact: [email protected] SOURCE Phenomix Sciences

JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just executed Cooperative Research and Development Agreement (CRADA) contract in conjunction with the Exalted Warrior Foundation out of Tampa Florida and three other companies. The six-week safety study subjects will be current active-duty and retired military volunteers for a period of six weeks beginning immediately after execution of Institutional Review Board (IRB) Approval. "The significance of this new development with Halberd IP to the ongoing crisis of depression and PTSD leading into suicidal ideation in our military is critical", relayed Halberd's CEO, William Hartman. This effort kicks off a highly innovative CRADA to significantly reduce anxiety, depression, and addiction symptoms as well as PTSD and Suicidal Ideation in our active duty servicemembers and veterans. This four-company approach evolved from extensive discussions and numerous meetings over the last four months with the key players, and involves not only key pharmacological/nutraceutical interventions, but also adjunct therapies while integrating 24/7 physiological and psychological patient tracking technologies via cloud-based systems developed by the team with new biomarker assessments. Halberd's patented LDN+ drug uniquely combines drugs previously approved by the FDA and widely used both individually and in a compounded formulation for many years. In combination, the drugs are believed to act as an antagonist against chemical and alcohol addiction and to relieve pain and anxiety linked to more severe mental health issues facing our military today. Pending the results of this limited pilot safety trial, and the results anticipated, higher volumes and more extensive tests of military personnel and veterans will be launched in less than 2 months. The clear pathway forward is to then obtain FDA clearance for the combined new pharmaceutical. William A. Hartman, Chairman, President & CEO of Halberd Corporation stated, "This is a huge step forward for Halberd Corporation to have one of our technology products, LDN+, involved in such a targeted clinical trial addressing a very significant issue with both the military but also civilian mental illness". To stay updated on the latest developments from Halberd, subscribe by submitting this form. ( ) For more information please contact: William A. Hartman w.hartman@halberdcorporation.com support@halberdcorporation.com Twitter: @HalberdC Note: Studies under this CRADA are funded by Non-Dilutive Financing, Participation in Ultimate Success Only. About Exalted Warrior Foundation "Exalted Warriors Foundation is a 501(c)(3) nonprofit that serves wounded warriors in the active military, veteran hospital facilities, and veterans within communities around the country." About Halberd Corporation Halberd Corporation (OTC-PINK:HALB), a publicly traded entity on the OTC Market, adheres fully to OTC Market reporting regulations. Following its restructuring in April 2020, Halberd secured exclusive global rights to three granted patents and submitted 22 associated provisional, PCT, or utility patent applications. This strategic move aims to augment the company's value for stockholders and generate interest from potential development partners. Safe Harbor Notice Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release. (C) 2024, Halberd Corporation SOURCE: Halberd Corporation View the original press release on accesswire.com